ACP
CYTK icon

Acuta Capital Partners’s Cytokinetics CYTK Stock Holding History

Acuta Capital Partners’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-357,500
Closed -$7.74M – 55
2020
Q3 		$7.74M Buy
+357,500
New +$8.36M 2.1% 16
2016
Q3 		– Sell
-140,969
Closed -$1.34M – 70
2016
Q2 		$1.34M Buy
+140,969
New +$1.16M 0.64% 39

Other funds holding CYTK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Acuta Capital Partners's CYTK Position: Q4 2020 in Review

Acuta Capital Partners sold out of Cytokinetics (CYTK) in Q4 2020, closing a stake of 357,500 shares — an estimated $7.74M sold.

Acuta Capital Partners first reported a position in CYTK in Q2 2016 and held it in 2 quarters. The position peaked at $7.74M in Q3 2020. 178 funds tracked by Wall St. Rank hold CYTK as of Q4 2020.

  • Acuta Capital Partners reported no remaining Cytokinetics position as of Q4 2020 after selling out during the quarter.
  • Acuta Capital Partners sold 357,500 Cytokinetics shares in Q4 2020, an estimated $7.74M.
  • Acuta Capital Partners first reported a position in Cytokinetics in Q2 2016 and held it in 2 quarters.
  • Acuta Capital Partners's Cytokinetics position peaked at $7.74M in Q3 2020.
  • 178 funds tracked by Wall St. Rank held Cytokinetics as of Q4 2020.

Based on Acuta Capital Partners's 13F filing for Q4 2020, filed 16 Feb 2021.